Unique ID issued by UMIN | UMIN000004823 |
---|---|
Receipt number | R000005732 |
Scientific Title | Transcoronary Infusion of Cardiac Progenitor Cells in Patients with Single Ventricle Physiology (TICAP) |
Date of disclosure of the study information | 2011/01/05 |
Last modified on | 2013/01/08 09:49:12 |
Transcoronary Infusion of Cardiac Progenitor Cells in Patients with Single Ventricle Physiology (TICAP)
Cell Therapy in Patients with Single Ventricle Physiology
Transcoronary Infusion of Cardiac Progenitor Cells in Patients with Single Ventricle Physiology (TICAP)
Cell Therapy in Patients with Single Ventricle Physiology
Japan |
Children with hypoplastic left heart syndrome or related single ventricle physiology
Cardiology | Pediatrics | Cardiovascular surgery |
Child |
Others
NO
The purpose of this study is to test the safety and feasibility of intracoronary infusion of autologous cardiac progenitor cells in children with single ventricle physiology.
Efficacy
Confirmatory
Pragmatic
Phase I
Monitoring major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.
Monitoring the rate of composite serious adverse events with death excluded and the rate of other complication.
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
The study patients will be involving 7 treated and 7 control subjects. Autologous cardiac progenitor cells are isolated from patients' own cardiac tissues obtained during palliative shunt procedure. Patients will receive 0.3 million/kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
staged shunt procedures include Norwood-Glenn, Glenn or Fonatan operation
0 | years-old | <= |
6 | years-old | >= |
Male and Female
Infants with single ventricle physiology undergoing second to third palliative shunt surgeries will be recruited into the study. Patients between 0 and 6 years of age are eligible if written informed consent can be obtained.
Exclusion criteia are the presence of cardiogenic shock, Eisenmenger syndrome, uncontrollable arrhythmia, severe chronic diseases, infections, cancer, or unwillingness to participate.
14
1st name | |
Middle name | |
Last name | Hidemasa Oh |
Okayama University Hospital
Department of Regenerative Medicine, Center for Innovative Clinical Medicine
2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
086-235-6506
1st name | |
Middle name | |
Last name | Rie Yokoyama |
Okayama University Hospital
Department of Cardiovascular Surgery
2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
086-235-7357
http://okayama-u-cvs.jp/siniryo.html
hidemasa@md.okayama-u.ac.jp
Center for Innovative Clinical Medicine, Okayama University Hospital
Okayama University Hospital
Japan
NO
岡山大学病院(岡山県)
2011 | Year | 01 | Month | 05 | Day |
Unpublished
Completed
2010 | Year | 12 | Month | 22 | Day |
2011 | Year | 01 | Month | 01 | Day |
2013 | Year | 01 | Month | 31 | Day |
2011 | Year | 01 | Month | 05 | Day |
2013 | Year | 01 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005732
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |